Introduction:
The US Food and Drug Administration (FDA) is investigating the side effects of the obesity drugs semaglutide and tirzepatide. The drugs are GLP-1 agonists, and the investigation is focused on whether they increase the risk of suicidal thoughts. The European Medicines Agency (EMA) is also conducting a similar investigation. The FDA’s investigation was prompted by reports of suicidal thoughts and other side effects from patients taking GLP-1 agonists.
- The FDA is investigating the side effects of semaglutide and tirzepatide, which are GLP-1 agonists.
- The investigation is focused on whether these drugs increase the risk of suicidal thoughts.
- The European Medicines Agency is also conducting a similar investigation.
- The FDA’s investigation was prompted by reports of suicidal thoughts and other side effects from patients taking GLP-1 agonists.
- Both Novo Nordisk and Eli Lilly, the developers of the drugs, are working closely with the FDA during the investigation.
Conclusion:
The FDA is investigating the potential suicide risk associated with the use of GLP-1 agonists, specifically semaglutide and tirzepatide. This investigation was prompted by reports of suicidal thoughts and other side effects from patients taking these drugs. The European Medicines Agency is also conducting a similar investigation. Both Novo Nordisk and Eli Lilly, the developers of the drugs, are cooperating with the FDA during the investigation. The results of the investigation will have implications for the use of GLP-1 agonists in the treatment of obesity and diabetes.
